Unlocking the value of Digital and AI partnerships for Biopharma: in conversation with PathAI
24 September 2024
In the inaugural episode of Baringa's Pharmaceutical and Life Sciences podcast, Baringa’s expert in Pharmaceuticals and Life Sciences, Josh Elliott is joined by Eric Walk, Chief Medical Officer at PathAI, to explore how strategic partnerships between digital and AI, and biopharma organisations are shaping the future of precision medicine.
Discover how to become a biopharma partner of choice, by overcoming key challenges faced when partnering with digital and AI organisations.
Listen on Spotify or on Amazon Music
View a transcript of this podcast here
About our host:
Josh Elliott, expert in Pharmaceuticals and Life Sciences
Josh helps global BioPharma organisations navigate their most complex business transformations with his experience ranging from pre-clinical research through to commercialisation. His specialism and passion is in helping his BioPharma clients optimise how they strategically partner with the wider ecosystem to maximise outcomes, having advised multiple market-leading strategic alliances and helped set up partnering operating models for organisations as a whole. His breadth of business transformation, R&D content knowledge, and people change expertise enables him to tailor a wide-range of tools and methods to the specific problem to solve, whether this involves utilising innovative digital technologies, embedding operational excellence and agility, or embedding behavioural change.
About our guest:
Eric Walk, Chief Medical Officer, PathAI
Dr. Eric Walk is head of the Medical group at PathAI, overseeing the Precision Medicine, Clinical Science, Quality and Regulatory teams. He has over 20 years of experience in precision medicine, oncology drug development and IVD companion diagnostics development. Prior to joining PathAI, Eric was Chief Medical and Scientific Officer at Roche Tissue Diagnostics/Ventana Medical Systems, where he led Medical & Scientific Affairs, overseeing the validation and FDA clearance/approval of multiple 510k and PMA IVD assays, companion diagnostics and digital pathology algorithms. Eric began his industry career at Novartis Oncology, where he held positions in Early Clinical Development and Translational Medicine, working to implement biomarker and precision medicine strategies for early and late stage targeted oncology therapeutics.
Related Insights
How powerful partnerships can unlock digital health innovation
Strategic partnerships offer an attractive route to unlock innovation within digital health however current failure rates sit at 60%. How can you build powerful partnerships?
Read more
The Power of Partnerships in Pharma
How can strategic partnerships realise their potential within pharma and life sciences?
Read more
Building stronger strategic partnerships in R&D
The establishment of strategic partnerships is increasingly recognised as a means to enhance innovation and drive future growth within research and development (R&D).
Read moreAre digital and AI delivering what your business needs?
Digital and AI can solve your toughest challenges and elevate your business performance. But success isn’t always straightforward. Where can you unlock opportunity? And what does it take to set the foundation for lasting success?